Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award



     Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award

PR Newswire

EXTON, Pa., Feb. 4, 2013

EXTON, Pa., Feb. 4, 2013 /PRNewswire/ -- Morphotek^® Inc., a subsidiary of
Eisai Inc., announced today that its recently opened 60,000-square-foot pilot
plant for the production of biological-based therapeutics to support
early-stage clinical trials has been designated the 2013 Facility of the Year
in the Sustainability category in a competition sponsored by the International
Society for Pharmaceutical Engineering (ISPE), INTERPHEX, and Pharmaceutical
Processing magazine. The award was bestowed by a panel of experts, consisting
of senior-level executives from multiple global pharmaceutical companies, who
judged 27 projects from various countries.

The Morphotek pilot plant project was initiated in 2008, with groundbreaking
occurring in 2010 and construction being completed in late 2011.  The company
invested $80 million in the facility, which encompasses a current Good
Manufacturing Practice (cGMP) grade pilot plant and office space for support
functions, enabling Morphotek to maximize the efficiencies of its product
development process and move closer to its goal of becoming a fully integrated
biopharmaceutical company.

"Eisai and Morphotek are committed to developing drugs in a cost-effective
manner for our patients, and that is reflected in the design and operation of
our energy efficient, state-of-the-art manufacturing facility," said Dr.
Philip Sass, Morphotek's Executive Vice President and Chief Operations
Officer. "We are honored to receive this prestigious award."

The judges said the Morphotek pilot plant utilized a variety of design and
construction features that made it stand out from other entries in the
Sustainability category, including the following:

  o It was built on a Brownfield site, giving new life to a previously
    abandoned and contaminated site through soil remediation and  the
    demolition of antiquated buildings.
  o Building materials used for the plant were all purchased within 500 miles
    of the plant to decrease the amount of energy used for shipping.
  o The project team used Building Information Modeling (BIM) software to
    integrate the best sustainable decisions into the design process.

In addition, Morphotek incorporated a number of "green initiatives" into the
design of the facility. These include the use of recycled materials (such as
cinder blocks and structured metal) from the building that used to be on the
site; solar panels; timers and motion sensors for lights and heating/cooling;
parking for low-emission vehicles; the use of low chemical-emitting paints and
plastics; and a comprehensive water and energy plan.   

The award will be officially presented to Morphotek representatives in April
at the annual Leadership Dinner at INTERPHEX 2013 in New York City. The
company will also be recognized at the ISPE Annual Meeting in November, in
addition to being featured in upcoming issues of two magazines, Pharmaceutical
Processing and Pharmaceutical Engineering. 

About Morphotek
Morphotek^® Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company
specializing in the development of protein and antibody products through the
use of a novel and proprietary gene evolution technology.  The technology has
been successfully applied to a broad variety of cell lines and organisms to
yield genetically diverse offspring that are suitable for pharmaceutical
product development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and improved
output traits for commercial applications.  The company is currently focusing
its platform on the development and manufacturing of therapeutic antibodies
for the treatment of cancer, inflammation and infectious disease.  For more
information, please visit www.morphotek.com.  

About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in
the United States in 1997. Since that time, Eisai Inc. has rapidly grown to
become a fully integrated pharmaceutical business. Eisai's key areas of
commercial focus are neurology and oncology. The company serves as the U.S.
pharmaceutical operation of Eisai Co., Ltd., a research-based human health
care (hhc) company that discovers, develops and markets products throughout
the world. 

Eisai has a global product creation organization that includes U.S.-based R&D
facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as
well as manufacturing facilities in Maryland and North Carolina. The company's
areas of R&D focus include neuroscience; oncology; vascular, inflammatory and
immunological reaction; and antibody-based programs.  For more information
about Eisai, please visit www.eisai.com/us.

Contacts: Media Inquiries         Investor Inquiries
          Terry Cushmore          Rod Dausch
          Morphotek, Inc.         Morphotek, Inc.
          610-423-6197            610-423-6111
          tcushmore@morphotek.com Dausch@morphotek.com
          Media Inquiries         Investor Inquiries
          Lynn Kenney             Alex Scott
          Eisai Inc.              Eisai Inc.
          201-746-2294            201-746-2177
          lynn_kenney@eisai.com   alex_scott@eisai.com

SOURCE Morphotek Inc.

Website: http://www.eisai.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement